Text Size

Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier:
NCT00755846
First received: September 17, 2008
Last updated: February 1, 2012
Last verified: February 2012
History of Changes
  Purpose

The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with type 2 diabetes.


Condition Intervention Phase
Diabetes Mellitus
 Drug: Alogliptin
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients With Type 2 Diabetes, Who Are Either Receiving No Current Treatment or Currently Treated With Diet and Exercise, Sulfonylurea, Metformin or a Combination of Sulfonylurea and Metformin

Resource links provided by NLM:

Drug Information available for: Alogliptin
U.S. FDA Resources

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:
  • Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85. [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at day 85 or final visit and glycosylated hemoglobin collected at baseline.


Secondary Outcome Measures:
  • Change From Baseline in Glycosylated Hemoglobin at Day 43. [ Time Frame: Baseline and Day 43. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at day 43 and glycosylated hemoglobin collected at baseline.

  • Change From Baseline in Fasting Plasma Glucose (Day 43). [ Time Frame: Baseline and Day 43 ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at day 43 and fasting plasma glucose collected at baseline.

  • Change From Baseline in Fasting Plasma Glucose (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at day 85 or final visit and fasting plasma glucose collected at baseline.

  • Change From Baseline in Fasting Fructosamine (Day 43). [ Time Frame: Baseline and Day 43. ] [ Designated as safety issue: No ]
    The change between the value of fasting fructosamine collected at day 43 and fasting fructosamine collected at baseline.

  • Change From Baseline in Fasting Fructosamine (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between the value of fasting fructosamine collected at day 85 or final visit and fasting fructosamine collected at baseline.

  • Change From Baseline in Total Cholesterol (Day 43). [ Time Frame: Baseline and Day 43 ] [ Designated as safety issue: No ]
    The change between the value of cholesterol collected at day 43 and cholesterol collected at baseline.

  • Change From Baseline in Total Cholesterol (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between the value of cholesterol collected at day 85 or final visit and cholesterol collected at baseline.

  • Change From Baseline in High-Density Lipoprotein Cholesterol (Day 43). [ Time Frame: Baseline and Day 43. ] [ Designated as safety issue: No ]
    The change between high-density lipoprotein cholesterol collected at day 43 and high-density lipoprotein cholesterol collected at baseline.

  • Change From Baseline in High-Density Lipoprotein Cholesterol (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between high-density lipoprotein cholesterol collected at day 85 or final visit and high-density lipoprotein cholesterol collected at baseline.

  • Change From Baseline in Low-Density Lipoprotein Cholesterol (Day 43). [ Time Frame: Baseline and Day 43. ] [ Designated as safety issue: No ]
    The change between low-density lipoprotein cholesterol collected at day 43 and low-density lipoprotein cholesterol collected at baseline.

  • Change From Baseline in Low-Density Lipoprotein Cholesterol (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between low-density lipoprotein cholesterol collected at day 85 or final visit and low-density lipoprotein cholesterol collected at baseline.

  • Change From Baseline in Triglycerides (Day 43). [ Time Frame: Baseline and Day 43. ] [ Designated as safety issue: No ]
    The change between triglycerides collected at day 43 and triglycerides collected at baseline.

  • Change From Baseline in Triglycerides (Day 85). [ Time Frame: Baseline and Day 85. ] [ Designated as safety issue: No ]
    The change between triglycerides collected at day 85 or final visit and triglycerides collected at baseline.

  • Mean Percent Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg/dL). [ Time Frame: 85 Days. ] [ Designated as safety issue: No ]
    The incidence of marked hyperglycemia occurring in participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during study. Overall mean obtained by weighting the hyperglycemia percent incidence values at each time point by number of days in between visits. Mean percent incidence of marked hyperglycemia at each time point is the percent of self-monitored blood glucose measurements greater than or equal to 200 mg per dL, calculated per participant and then averaged across population.


Enrollment: 265
Study Start Date: March 2005
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alogliptin 6.25 mg QD Drug: Alogliptin
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
  • Alogliptin
  • SYR-322
  • SYR110322
Experimental: Alogliptin 12.5 mg QD Drug: Alogliptin
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
  • Alogliptin
  • SYR-322
  • SYR110322
Experimental: Alogliptin 25 mg QD Drug: Alogliptin
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
  • Alogliptin
  • SYR-322
  • SYR110322
Experimental: Alogliptin 50 mg QD Drug: Alogliptin
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
  • Alogliptin
  • SYR-322
  • SYR110322
Experimental: Alogliptin 100 mg QD Drug: Alogliptin
Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
  • Alogliptin
  • SYR-322
  • SYR110322
Placebo Comparator: Placebo QD Drug: Placebo
Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.

Detailed Description:

Of the approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, 90% to 95% have type 2 diabetes mellitus. The prevalence of type 2 diabetes mellitus varies among racial and ethnic populations and has been shown to increase with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a disproportionate increase in the elderly population will result in a marked increase in diabetic patients, placing an ever-increasing burden on families and the health care system.

In response to this problem, Takeda Global Research & Development Center, Inc. is developing SYR-322 (alogliptin), a selective, orally available inhibitor of the enzyme dipeptidyl peptidase IV. Dipeptidyl peptidase IV is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 14 Weeks. Multiple procedures will occur at each visit which may include blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations and electrocardiograms.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has type 2 diabetes mellitus and were either receiving no current treatment or currently treated with a sulfonylurea, metformin, or a combination of a sulfonylurea and metformin but experiencing inadequate glycemic control. Subjects qualified as receiving no current treatment if 1 of the following conditions applied:

    • Subject was newly diagnosed (ie, had not received any treatment).
    • Subject was treated with diet and exercise alone for the 3 months prior to Screening
    • Subject had received <7 continuous days of any antidiabetic therapy within the 3 months prior to Screening.
    • Subject had a diagnosis of type 2 diabetes mellitus based on current American Diabetes Association criteria: fasting plasma glucose ≥126 mg/dL, oral glucose tolerance test at 2 hours after administration of the glucose load must have been ≥200 mg/dL, or symptoms of diabetes plus casual plasma glucose ≥200 mg/dL.
  • Body mass index ≥23 kg/m2 and ≤40 kg/m2.
  • Fasting C-peptide concentration ≥0.8 ng/mL.
  • Glycosylated hemoglobin concentration between 6.8% and 11.0%.
  • Fasting plasma glucose >126 mg/dL at Screening.

  • No treatment within the 3 months prior to Screening with any other agents known to have effects on glucose (other than as described above, a sulfonylurea, metformin, or a combination of a sulfonylurea and metformin in subjects on antidiabetics), including but not limited to the following:

    • Other antidiabetic agents
    • Investigational antidiabetic agents
    • Niacin
    • Regular use of systemic glucocorticoids.
    • No treatment within the 3 months prior to Screening with weight-loss drugs
    • If taking other non-excluded medications, must have been on a stable dose of medication for at least 4 weeks.
  • Diastolic blood pressure ≤110 mm Hg and a systolic pressure of ≤180 mm Hg.
  • Female subjects could neither be pregnant (confirmed by laboratory testing) nor lactating, and if of childbearing potential must have been practicing adequate contraception.
  • Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
  • No major illness or debility that in the investigator's opinion prohibited the subject from completing the study.
  • Hemoglobin ≥12 g/dL for males and ≥10 g/dL for females.
  • Hepatic transaminase ≤2 x upper limit of normal.

Exclusion Criteria:

  • History of cancer, other than squamous cell or basal cell carcinoma of the skin, that had not been in full remission for at least 1 year prior to Screening.
  • History of proteinuria >1000 mg/day on a 12- or 24-hour urine collection OR a urine albumin/creatinine ratio >1000 μg/mg at Screening. If elevated, the subject was to be rescreened within 1 week.
  • Serum creatinine ≥2.0 mg/dL.
  • History of proliferative diabetic retinopathy OR any history of laser-treated retinopathy.
  • History of treated peripheral or autonomic neuropathy.
  • History of systolic dysfunction congestive heart failure.
  • History of myocardial infarction within 1 year prior to Screening.
  • History of ulcerative colitis or Crohn's disease.
  • History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
  • History of a psychiatric disorder that would affect the subject's ability to participate in the study.
  • History of anaphylactic reaction(s) to any drug.
  • History of angioedema.
  • History of alcohol or substance abuse within the last 2 years.
  • History of any surgery that could potentially affect the absorption of the study drug.
  • Receipt of any investigational drug within the preceding 30 days or a history of receipt of an investigational antidiabetic drug within the preceding 90 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00755846

Sponsors and Collaborators
Takeda Global Research & Development Center, Inc.
Investigators
Study Director: VP Biological Sciences Takeda Global Research & Development Center, Inc.
  More Information

Publications:

Responsible Party: Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00755846     History of Changes
Other Study ID Numbers: SYR-322-003, U1111-1113-8352
Study First Received: September 17, 2008
Results First Received: June 8, 2011
Last Updated: February 1, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda Global Research & Development Center, Inc.:
Diabetes Mellitus
Drug Therapy
Diabetes Mellitus, Type II
 Type 2 Diabetes Mellitus
Hyperinsulinism
Insulin Resistance

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Alogliptin
Dipeptidyl-Peptidase IV Inhibitors
 Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013